Skip to main content

Advertisement

SpringerLink
Log in

Drug delivery for the treatment of endometriosis and uterine fibroids

  • Review Article
  • Published:
Drug Delivery and Translational Research Aims and scope Submit manuscript

Abstract

Endometriosis and uterine fibroids (also known as uterine leiomyomas) are serious medical conditions affecting large numbers of women worldwide. Many women are asymptomatic but those with symptoms require medical intervention to relieve chronic pain and dysmenorrhea and to address infertility. Drug delivery has played a role in reducing some of the symptoms associated with endometriosis and uterine fibroids. Use of drug delivery systems for both conditions can roughly be divided into two categories: (1) existing systems designed for other indications such as contraception for symptomatic relief and (2) development of novel systems aimed at addressing some of the underlying biochemical changes associated with endometriosis and uterine fibroids such as oxidative stress, angiogenesis, and matrix degradation. The latter drug delivery approaches rely heavily on nanotechnology. Existing systems that deliver estrogens and/or progestins include vaginal rings, transdermal patches, and intrauterine systems. Long-acting implantable contraceptives such as Implanon® and injectables such as Depo-Provera® have found use in treating endometriosis. Similarly, long-acting GnRH products (e.g., Lupron Depot®) are used to treat endometriosis. Other drugs formulated in long-acting formulations include intravaginal rings capable of delivering selective progesterone receptor modulators, androgens such as danazol, and aromatase inhibitors (e.g., anastrozole). Nanoparticles composed of silica, poly(lactic-co-glycolic acid), cerium oxide, dendrimers, and chitosan/polyethyleneamine have all been investigated to improve treatment of endometriosis and to a lesser extent, uterine fibroids.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Giudice LC, Kao LC. Endometriosis. Lancet. 2004;364(9447):1789–99. doi:10.1016/S0140-6736(04)17403-5.

    Article  PubMed  Google Scholar 

  2. Guo SW, Wang Y. The prevalence of endometriosis in women with chronic pelvic pain. Gynecol Obstet Investig. 2006;62(3):121–30.

    Article  Google Scholar 

  3. Carlson KJ, Miller BA, Flower FJJ. The Maine Women’s Health Study: I. Outcomes of Hysterectomy Obstetrics & Gynecology. 1994;83(4):556–65.

    Article  CAS  Google Scholar 

  4. Zeitoun K, Takayama K, Michael MD, Bulun SE. Stimulation of aromatase P450 promoter (II) activity in endometriosis and its inhibition in endometrium are regulated by competitive binding of steroidogenic factor-1 and chicken ovalbumin upstream promoter transcription factor to the same cis-acting element. Mol Endocrinol. 1999;13(2):239–53. doi:10.1210/mend.13.2.0229.

    Article  CAS  PubMed  Google Scholar 

  5. Zeitoun KM, Bulun SE. Aromatase: a key molecule in the pathophysiology of endometriosis and a therapeutic target. Fertil Steril. 1999;72(6):961–9. doi:10.1016/S0015-0282(99)00393-3.

    Article  CAS  PubMed  Google Scholar 

  6. Zito G, Luppi S, Giolo E, Martinelli M, Venturin I, Di Lorenzo G, et al. Medical treatments for endometriosis-associated pelvic pain. Biomed Res Int. 2014;2014:191967. doi:10.1155/2014/191967.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Bedaiwy MA, Alfaraj S, Yong P, Casper R. New developments in the medical treatment of endometriosis. Fertil Steril. 2017; doi:10.1016/j.fertnstert.2016.12.025.

  8. Greene AD, Lang SA, Kendziorski JA, Sroga-Rios JM, Herzog TJ, Burns KA. Endometriosis: where are we and where are we going? Reproduction. 2016;152(3):R63–78. doi:10.1530/rep-16-0052.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Mehedintu C, Plotogea MN, Ionescu S, Antonovici M. Endometriosis still a challenge. Journal of Medicine and Life. 2014;7(3):349–57.

    CAS  PubMed  PubMed Central  Google Scholar 

  10. Stewart EA. Uterine fibroids. New England Journal of Medicine. 2015;372(17):1646–55. doi:10.1056/NEJMcp1411029.

  11. Day Baird D, Dunson DB, Hill MC, Cousins D, Schectman JM. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. American Journal of Obstetrics & Gynecology.188(1):100–7. doi:10.1067/mob.2003.99.

  12. Sengoba KS, Ghant MS, Okeigwe I, Mendoza G, Marsh EE. Racial/ethnic differences in women’s experiences with symptomatic uterine fibroids: a qualitative assessment. J Racial Ethn Health Disparities. 2017;4(2):178–83. doi:10.1007/s40615-016-0216-1.

    Article  PubMed  Google Scholar 

  13. Gliklich RE, Leavy MB, Velentgas P, Campion DM, Mohr P, Sabharwal R, et al. Identification of future research needs in the comparative management of uterine fibroid disease. Effective Health Care Program: Research Reports, Agency for Healthcare Research and Quality. 2011;31

  14. Cardozo ER, Clark AD, Banks NK, Henne MB, Stegmann BJ, Segars JH. The estimated annual cost of uterine leiomyomata in the United States. American Journal of Obstetrics & Gynecology. 2012;206(3):211.e1–.e9. doi:10.1016/j.ajog.2011.12.002.

  15. Stewart EA, Nicholson WK, Bradley L, Borah BJ. The burden of uterine fibroids for African-American women: results of a national survey. J Women's Health. 2013;22(10):807–16. doi:10.1089/jwh.2013.4334.

    Article  Google Scholar 

  16. ACOG Practice Bulletin No. 96: Alternatives to hysterectomy in the management of leiomyomas. Obstetrics & Gynecology. 2008;112(2, Part 1):387–400. doi:10.1097/AOG.0b013e318183fbab.

  17. Sangkomkamhang US, Lumbiganon P, Laopaiboon M, Mol BW. Progestogens or progestogen-releasing intrauterine systems for uterine fibroids. Cochrane Database Syst Rev. 2013;2:CD008994. doi:10.1002/14651858.CD008994.pub2.

    Google Scholar 

  18. Mercorio F, De Simone R, Di Spiezio SA, Cerrota G, Bifulco G, Vanacore F, et al. The effect of a levonorgestrel-releasing intrauterine device in the treatment of myoma-related menorrhagia. Contraception. 2003;67(4):277–80. doi:10.1016/S0010-7824(02)00522-X.

    Article  CAS  PubMed  Google Scholar 

  19. Pérez-López FR, Ornat L, Ceausu I, Depypere H, Erel CT, Lambrinoudaki I, et al. EMAS position statement: management of uterine fibroids. Maturitas. 2014;79(1):106–16. doi:10.1016/j.maturitas.2014.06.002.

    Article  PubMed  Google Scholar 

  20. Marret H, Fritel X, Ouldamer L, Bendifallah S, Brun J-L, De Jesus I, et al. Therapeutic management of uterine fibroid tumors: updated French guidelines. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2012;165(2):156–64. doi:10.1016/j.ejogrb.2012.07.030.

    Article  Google Scholar 

  21. Lukes AS, Moore KA, Muse KN, Gersten JK, Hecht BR, Edlund M, et al. Tranexamic acid treatment for heavy menstrual bleeding: a randomized controlled trial. Obstet Gynecol. 2010;116(4):865–75. doi:10.1097/AOG.0b013e3181f20177.

    Article  PubMed  Google Scholar 

  22. Friend DR. Development of controlled release systems over the past 50 years in the area of contraception. J Control Release. 2016;240:235–41. doi:10.1016/j.jconrel.2015.12.043.

    Article  CAS  PubMed  Google Scholar 

  23. Friend DR. Intravaginal rings: controlled release systems for contraception and prevention of transmission of sexually transmitted infections. Drug Deliv Transl Res. 2011;1(3):185–93. doi:10.1007/s13346-011-0024-4.

    Article  CAS  PubMed  Google Scholar 

  24. Vercellini P, Barbara G, Somigliana E, Bianchi S, Abbiati A, Fedele L. Comparison of contraceptive ring and patch for the treatment of symptomatic endometriosis. Fertil Steril. 2010;93(7):2150–61. doi:10.1016/j.fertnstert.2009.01.071.

    Article  CAS  PubMed  Google Scholar 

  25. Creinin MD, Meyn LA, Borgatta L, Barnhart K, Jensen J, Burke AE et al. Multicenter comparison of the contraceptive ring and patch: a randomized controlled trial. Obstetrics & Gynecology. 2008;111(2, Part 1):267–77. doi:10.1097/01.AOG.0000298338.58511.d1.

  26. Fraser IS. Added health benefits of the levonorgestrel contraceptive intrauterine system and other hormonal contraceptive delivery systems. Contraception. 2013;87(3):273–9. doi:10.1016/j.contraception.2012.08.039.

    Article  CAS  PubMed  Google Scholar 

  27. Kim M-L, Seong SJ. Clinical applications of levonorgestrel-releasing intrauterine system to gynecologic diseases. Obstet Gynecol Sci. 2013;56(2):67–75.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Vercellini P, Viganò P, Somigliana E. The role of the levonorgestrel-releasing intrauterine device in the management of symptomatic endometriosis. Curr Opin Obstet Gynecol. 2005;17(4):359–65.

    Article  PubMed  Google Scholar 

  29. Bahamondes L, Petta CA, Fernandes A, Monteiro I. Use of the levonorgestrel-releasing intrauterine system in women with endometriosis, chronic pelvic pain and dysmenorrhea. Contraception. 2007;75(6):S134–S9. doi:10.1016/j.contraception.2006.12.008.

    Article  CAS  PubMed  Google Scholar 

  30. Matorras R, Ballesteros A, Prieto B, Ocerin I, Exposito A, Pijoan JI, et al. Efficacy of the levonorgestrel-releasing intrauterine device in the treatment of recurrent pelvic pain in multitreated endometriosis. J Reprod Med. 2011;56(11–12):497–503.

    CAS  PubMed  Google Scholar 

  31. Tanmahasamut P, Rattanachaiyanont M, Angsuwathana S, Techatraisak K, Indhavivadhana S, Leerasiri P. Postoperative levonorgestrel-releasing intrauterine system for pelvic endometriosis-related pain: a randomized controlled trial. Obstet Gynecol. 2012;119(3):519–26. doi:10.1097/AOG.0b013e31824264c3.

    Article  PubMed  Google Scholar 

  32. Croxatto HB, Makarainen L. The pharmacodynamics and efficacy of Implanon. An overview of the data. Contraception. 1998;58(6 Suppl):91S–7S.

    Article  CAS  PubMed  Google Scholar 

  33. Yisa SB, Okenwa AA, Husemeyer RP. Treatment of pelvic endometriosis with etonogestrel subdermal implant (Implanon®). Journal of Family Planning and Reproductive Health Care. 2005;31(1):67–70. doi:10.1783/0000000052972799.

    Article  PubMed  Google Scholar 

  34. Vercellini P, De Giorgi O, Oldani S, Cortesi I, Panazza S, Crosignani PG. Depot medroxyprogesterone acetate versus an oral contraceptive combined with very-low-dose danazol for long-term treatment of pelvic pain associated with endometriosis. American Journal of Obstetrics & Gynecology. 1996;175(2):396–401. doi:10.1016/S0002-9378(96)70152-7.

    Article  CAS  Google Scholar 

  35. Yuan P, Huang Y, Wu H, Teng Z, Zhang J, Xin X. Induction of a local pseudo-pregnancy via levonorgestrel-loaded microspheres for the treatment of endometriosis in a rabbit model. Hum Reprod. 2010;25(2):462–9. doi:10.1093/humrep/dep386.

    Article  CAS  PubMed  Google Scholar 

  36. Rice VM. Conventional medical therapies for endometriosis. Ann N Y Acad Sci. 2002;955(1):343–52. doi:10.1111/j.1749-6632.2002.tb02795.x.

    Article  PubMed  Google Scholar 

  37. Kettel LM, Murphy AA, Morales AJ, Yen SSC. Preliminary report on the treatment of endometriosis with low-dose mifepristone (RU 486). American Journal of Obstetrics & Gynecology. 1998;178(6):1151–6. doi:10.1016/S0002-9378(98)70316-3.

    Article  CAS  Google Scholar 

  38. Brache V, Sitruk-Ware R, Williams A, Blithe D, Croxatto H, Kumar N, et al. Effects of a novel estrogen-free, progesterone receptor modulator contraceptive vaginal ring on inhibition of ovulation, bleeding patterns and endometrium in normal women. Contraception. 2013;85(5):480–8. doi:10.1016/j.contraception.2011.10.003.

    Article  Google Scholar 

  39. Huang Y, Jensen JT, Brache V, Cochon L, Williams A, Miranda MJ, et al. A randomized study on pharmacodynamic effects of vaginal rings delivering the progesterone receptor modulator ulipristal acetate: research for a novel estrogen-free, method of contraception. Contraception. 2014;90(6):565–74. doi:10.1016/j.contraception.2014.08.006.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Brenner RM, Slayden OD, Nath A, Tsong YY, Sitruk-Ware R. Intrauterine administration of CDB-2914 (ulipristal) suppresses the endometrium of rhesus macaques. Contraception. 2010;81(4):336–42. doi:10.1016/j.contraception.2009.11.004.

    Article  CAS  PubMed  Google Scholar 

  41. Greenblatt RB, Dmowski WP, Mahesh VB, Scholer HFL. Clinical studies with an antigonadotropin-Danazol. Fertil Steril. 1971;22(2):102–12. doi:10.1016/S0015-0282(16)38045-1.

    Article  CAS  PubMed  Google Scholar 

  42. Crosignani P, Olive D, Bergqvist A, Luciano A. Advances in the management of endometriosis: an update for clinicians. Hum Reprod Update. 2006;12(2):179–89. doi:10.1093/humupd/dmi049.

    Article  CAS  PubMed  Google Scholar 

  43. Buttram VC Jr, Reiter RC, Ward S. Treatment of endometriosis with danazol: report of a 6-year prospective study. Fertil Steril. 1985;43(3):353–60. doi:10.1016/S0015-0282(16)48431-1.

    Article  PubMed  Google Scholar 

  44. Nomura K, Murakami K, Shozu M, Nakama T, Yui N, Inoue M. Local application of danazol-loaded hyaluronic acid hydrogel to endometriosis in a rat model. Fertil Steril. 1990;85:1157–67. doi:10.1016/j.fertnstert.2005.08.057.

    Article  Google Scholar 

  45. Igarashi M. A new therapy for pelvic endometriosis and uterine adenomyosis: local effect of vaginal and intrauterine danazol application. Asia Oceania J Obstet Gynaecol. 1990;16(1):1–12.

    Article  CAS  PubMed  Google Scholar 

  46. Igarashi M, Iizuka M, Abe Y, Ibuki Y. Novel vaginal danazol ring therapy for pelvic endometriosis, in particular deeply infiltrating endometriosis. Hum Reprod. 1998;13(7):1952–6.

    Article  CAS  PubMed  Google Scholar 

  47. Zhang X, Yuan H, Deng L, Hu F, Ma J, Lin J. Evaluation of the efficacy of a danazol-loaded intrauterine contraceptive device on adenomyosis in an ICR mouse model. Hum Reprod. 2008;23(9):2024–30. doi:10.1093/humrep/den208.

    Article  CAS  PubMed  Google Scholar 

  48. Plourde PV, Dyroff M, Dukes M. Arimidex®: a potent and selective fourth-generation aromatase inhibitor. Breast Cancer Res Treat. 1994;30(1):103–11. doi:10.1007/BF00682745.

    Article  CAS  PubMed  Google Scholar 

  49. Rotgeri A, Korolainen H, Sundholm O, Schmitz H, Fuhrmann U, Prelle K, et al. Characterization of anastrozole effects, delivered by an intravaginal ring in cynomolgus monkeys. Hum Reprod. 2015;30(2):308–14. doi:10.1093/humrep/deu315.

    Article  CAS  PubMed  Google Scholar 

  50. Reinecke I, Schultze-Mosgau M-H, Nave R, Schmitz H, Ploeger BA. Model-based dose selection for intravaginal ring formulations releasing anastrozole and levonorgestrel intended for the treatment of endometriosis symptoms. The Journal of Clinical Pharmacology. 2016:n/a-n/a. doi:10.1002/jcph.846.

  51. Schultze-Mosgau MH, Waellnitz K, Nave R, Klein S, Kraetzschmar J, Rautenberg T, et al. Pharmacokinetics, pharmacodynamics, safety and tolerability of an intravaginal ring releasing anastrozole and levonorgestrel in healthy premenopausal women: a phase 1 randomized controlled trial. Hum Reprod. 2016;31(8):1713–22. doi:10.1093/humrep/dew145.

    Article  PubMed  Google Scholar 

  52. Remorgida V, Abbamonte LH, Ragni N, Fulcheri E, Ferrero S. Letrozole and desogestrel-only contraceptive pill for the treatment of stage IV endometriosis. Aust N Z J Obstet Gynaecol. 2007;47(3):222–5. doi:10.1111/j.1479-828X.2007.00722.x.

    Article  PubMed  Google Scholar 

  53. Ferrero S, Camerini G, Seracchioli R, Ragni N, Venturini PL, Remorgida V. Letrozole combined with norethisterone acetate compared with norethisterone acetate alone in the treatment of pain symptoms caused by endometriosis. Hum Reprod. 2009;24(12):3033–41. doi:10.1093/humrep/dep302.

    Article  CAS  PubMed  Google Scholar 

  54. Amsterdam LL, Gentry W, Jobanputra S, Wolf M, Rubin SD, Bulun SE. Anastrazole and oral contraceptives: a novel treatment for endometriosis. Fertil Steril. 2005;84(2):300–4. doi:10.1016/j.fertnstert.2005.02.018.

    Article  CAS  PubMed  Google Scholar 

  55. Donnez J, Binda MM, Donnez O, Dolmans M-M. Oxidative stress in the pelvic cavity and its role in the pathogenesis of endometriosis. Fertil Steril. 2016;106(5):1011–7. doi:10.1016/j.fertnstert.2016.07.1075.

    Article  CAS  PubMed  Google Scholar 

  56. May K, Becker CM. Endometriosis and angiogenesis. Minerva Ginecol. 2008;60(3):245–54.

    CAS  PubMed  Google Scholar 

  57. Ria R, Loverro G, Vacca A, Ribatti D, Cormio G, Roccaro AM, et al. Angiogenesis extent and expression of matrix metalloproteinase-2 and -9 agree with progression of ovarian endometriomas. Eur J Clin Investig. 2002;32(3):199–206. doi:10.1046/j.1365-2362.2002.00960.x.

    Article  CAS  Google Scholar 

  58. Singh AK, Chakravarty B, Chaudhury K. Nanoparticle-assisted combinatorial therapy for effective treatment of endometriosis. J Biomed Nanotechnol. 2015;11(5):789–804. doi:10.1166/jbn.2015.2020.

    Article  CAS  PubMed  Google Scholar 

  59. Somigliana E, Viganò P, Rossi G, Carinelli S, Vignali M, Panina-Bordignon P. Endometrial ability to implant in ectopic sites can be prevented by interleukin-12 in a murine model of endometriosis. Hum Reprod. 1999;14(12):2944–50. doi:10.1093/humrep/14.12.2944.

    Article  CAS  PubMed  Google Scholar 

  60. Olovsson M. Immunological aspects of endometriosis: an update. Am J Reprod Immunol. 2011;66:101–4. doi:10.1111/j.1600-0897.2011.01045.x.

    Article  PubMed  Google Scholar 

  61. Capobianco A, Rovere Querini P. Endometriosis, a disease of the macrophage. Frontiers in Immunology. 2013;4(9). doi:10.3389/fimmu.2013.00009.

  62. Jakopin Z. Murabutide revisited: a review of its pleiotropic biological effects. Curr Med Chem. 2013;20(16):2068–79.

    Article  CAS  PubMed  Google Scholar 

  63. Shimizu T, Iwamoto Y, Yanagihara Y, Ikeda K, Achiwa K. Combined effects of synthetic lipid a analogs or bacterial lipopolysaccharide with glucosaminylmuramyl dipeptide on antitumor activity against meth a fibrosarcoma in mice. Int J Immunopharmacol. 1992;14(8):1415–20. doi:10.1016/0192-0561(92)90013-B.

    Article  CAS  PubMed  Google Scholar 

  64. Antsiferova Y, Sotnikova N, Parfenyuk E. Different effects of the immunomodulatory drug GMDP immobilized onto aminopropyl modified and unmodified mesoporous silica nanoparticles upon peritoneal macrophages of women with endometriosis. Biomed Res Int. 2013;2013:924362. doi:10.1155/2013/924362.

    Article  PubMed  PubMed Central  Google Scholar 

  65. Augoulea A, Mastorakos G, Lambrinoudaki I, Christodoulakos G, Creatsas G. The role of the oxidative-stress in the endometriosis-related infertility. Gynecol Endocrinol. 2009;25(2):75–81. doi:10.1080/09513590802485012.

    Article  PubMed  Google Scholar 

  66. Szczepańska M, Koźlik J, Skrzypczak J, Mikołajczyk M. Oxidative stress may be a piece in the endometriosis puzzle. Fertil Steril. 2003;79(6):1288–93. doi:10.1016/S0015-0282(03)00266-8.

    Article  PubMed  Google Scholar 

  67. Celardo I, Pedersen JZ, Traversa E, Ghibelli L. Pharmacological potential of cerium oxide nanoparticles. Nano. 2011;3(4):1411–20. doi:10.1039/C0NR00875C.

    CAS  Google Scholar 

  68. Karakoti AS, Monteiro-Riviere NA, Aggarwal R, Davis JP, Narayan RJ, Self WT, et al. Nanoceria as antioxidant: synthesis and biomedical applications. JOM. 2008;60(3):33–7. doi:10.1007/s11837-008-0029-8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Chaudhury K, Babu KN, Singh AK, Das S, Kumar A, Seal S. Mitigation of endometriosis using regenerative cerium oxide nanoparticles. Nanomedicine. 2013;9(3):439–48. doi:10.1016/j.nano.2012.08.001.

    Article  CAS  PubMed  Google Scholar 

  70. Lima CS, de Medeiros BJL, Favacho HAS, dos Santos KC, de Oliveira BR, Taglialegna JC, et al. Pre-clinical validation of a vaginal cream containing copaiba oil (reproductive toxicology study). Phytomedicine. 2011;18(12):1013–23. doi:10.1016/j.phymed.2011.05.004.

    Article  CAS  PubMed  Google Scholar 

  71. Nogueira Neto J, Lindoso MJdS, Coelho LF, Carvalho RAF, Rodrigues TGPdM, Araújo AGPd et al. Changes in the volume and histology of endometriosis foci in rats treated with copaiba oil (Copaiferalangsdorffii). Acta Cirurgica Brasileira. 2011;26:20–4.

  72. de Almeida Borges VR, Tavares MR, da Silva JH, Tajber L, Boylan F, Ribeiro AF, et al. Development and characterization of poly(lactic-co-glycolic) acid nanoparticles loaded with copaiba oleoresin. Pharm Dev Technol. 2017;22:1–8. doi:10.1080/10837450.2017.1290107.

    Article  Google Scholar 

  73. de Almeida Borges VR, da Silva JH, Barbosa SS, Nasciutti LE, Cabral LM, de Sousa VP. Development and pharmacological evaluation of in vitro nanocarriers composed of lamellar silicates containing copaiba oil-resin for treatment of endometriosis. Mater Sci Eng C. 2016;64:310–7. doi:10.1016/j.msec.2016.03.094.

    Article  Google Scholar 

  74. Basta P, Majka M, Jozwicki W, Lukaszewska E, Knafel A, Grabiec M, et al. The frequency of CD25+CD4+ and FOXP3+ regulatory T cells in ectopic endometrium and ectopic decidua. Reprod Biol Endocrinol. 2010;8(1):116. doi:10.1186/1477-7827-8-116.

    Article  PubMed  PubMed Central  Google Scholar 

  75. Podgaec S, Rizzo LV, Fernandes LFC, Baracat EC, Abrao MS. CD4+CD25highFoxp3+ cells increased in the peritoneal fluid of patients with endometriosis. Am J Reprod Immunol. 2012;68(4):301–8. doi:10.1111/j.1600-0897.2012.01173.x.

    Article  CAS  PubMed  Google Scholar 

  76. Takahashi T, Tagami T, Yamazaki S, Uede T, Shimizu J, Sakaguchi N, et al. Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte–associated antigen 4. J Exp Med. 2000;192(2):303–10. doi:10.1084/jem.192.2.303.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol. 2008;8(6):467–77.

    Article  CAS  PubMed  Google Scholar 

  78. Liu Q, Ma P, Liu L, Ma G, Ma J, Liu X, et al. Evaluation of PLGA containing anti-CTLA4 inhibited endometriosis progression by regulating CD4 + CD25 + Treg cells in peritoneal fluid of mouse endometriosis model. Eur J Pharm Sci. 2017;96:542–50. doi:10.1016/j.ejps.2016.10.031.

    Article  CAS  PubMed  Google Scholar 

  79. Shakhbazau A, Isayenka I, Kartel N, Goncharova N, Seviaryn I, Kosmacheva S, et al. Transfection efficiencies of PAMAM dendrimers correlate inversely with their hydrophobicity. Int J Pharm. 2010;383(1–2):228–35. doi:10.1016/j.ijpharm.2009.09.020.

    Article  CAS  PubMed  Google Scholar 

  80. Wang N, Tan J, HJ D. Effect of lopfectamine-mediated endostatin gene therapy on human endmetriosis lesions in nude mice. Med J Chinese People's Liberation Army. 2005;34(12):1430–3.

    Google Scholar 

  81. Liu B, Wang NN, Wang ZL, Hong SS, Li JT, Ding HJ, et al. Improved nude mouse models for green fluorescence human endometriosis. J Obstet Gynaecol Res. 2010;36(6):1214–21. doi:10.1111/j.1447-0756.2010.01345.x.

    Article  PubMed  Google Scholar 

  82. Wang N, Liu B, Liang L, Wu Y, Xie H, Huang J, et al. Antiangiogenesis therapy of endometriosis using PAMAM as a gene vector in a noninvasive animal model. Biomed Res Int. 2014;2014:546479. doi:10.1155/2014/546479.

    PubMed  PubMed Central  Google Scholar 

  83. Knepper MA, Kwon T-H, Nielsen S. Molecular physiology of water balance. N Engl J Med. 2015;372(14):1349–58. doi:10.1056/NEJMra1404726.

    Article  CAS  PubMed  Google Scholar 

  84. Sebastian R, Chau E, Fillmore P, Matthews J, Price LA, Sidhaye V, et al. Epidermal aquaporin-3 is increased in the cutaneous burn wound. Burns. 2015;41(4):843–7. doi:10.1016/j.burns.2014.10.033.

    Article  CAS  PubMed  Google Scholar 

  85. Zou L-B, Zhang R-J, Tan Y-J, Ding G-L, Shi S, Zhang D, et al. Identification of estrogen response element in the aquaporin-2 gene that mediates estrogen-induced cell migration and invasion in human endometrial carcinoma. J Clin Endocrinol Metabol. 2011;96(9):E1399–E408. doi:10.1210/jc.2011-0426.

    Article  CAS  Google Scholar 

  86. Zhao M-D, Cheng J-L, Yan J-J, Chen F-Y, Sheng J-Z, Sun D-L, et al. Hyaluronic acid reagent functional chitosan-PEI conjugate with AQP2-siRNA suppressed endometriotic lesion formation. Int J Nanomedicine. 2016;11:1323–36. doi:10.2147/IJN.S99692.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  87. Iwase A, Kotani T, Goto M, Kobayashi H, Takikawa S, Nakahara T, et al. Possible involvement of CD10 in the development of endometriosis due to its inhibitory effects on CD44-dependent cell adhesion. Reprod Sci. 2014;21(1):82–8. doi:10.1177/1933719113488449.

    Article  PubMed  PubMed Central  Google Scholar 

  88. Harmon QE, Baird DD. Use of depot medroxyprogesterone acetate and prevalent leiomyoma in young African American women. Hum Reprod (Oxford, England). 2015;30(6):1499–504. doi:10.1093/humrep/dev069.

    Article  CAS  Google Scholar 

  89. Bouchard P, Chabbert-Buffet N. The history and use of the progesterone receptor modulator ulipristal acetate for heavy menstrual bleeding with uterine fibroids. Best Pract Res Clin Obstet Gynaecol. 2016; doi:10.1016/j.bpobgyn.2016.12.002.

  90. Goodwin SC, Spies JB. Uterine fibroid embolization. N Engl J Med. 2009;361(7):690–7. doi:10.1056/NEJMct0806942.

    Article  CAS  PubMed  Google Scholar 

  91. Gupta JK, Sinha A, Lumsden MA, Hickey M. Uterine artery embolization for symptomatic uterine fibroids. Cochrane Database Syst Rev. 2014;(12):CD005073. doi:10.1002/14651858.CD005073.pub4.

  92. Borovac T, Pelage JP, Kasselouri A, Prognon P, Guiffant G, Laurent A. Release of ibuprofen from beads for embolization: in vitro and in vivo studies. J Control Release. 2006;115(3):266–74. doi:10.1016/j.jconrel.2006.08.008.

    Article  CAS  PubMed  Google Scholar 

  93. Bédouet L, Moine L, Servais E, Beilvert A, Labarre D, Laurent A. Tunable delivery of niflumic acid from resorbable embolization microspheres for uterine fibroid embolization. Int J Pharm. 2016;511(1):253–61. doi:10.1016/j.ijpharm.2016.06.128.

    Article  PubMed  Google Scholar 

  94. Louguet S, Verret V, Bédouet L, Servais E, Pascale F, Wassef M, et al. Poly(ethylene glycol) methacrylate hydrolyzable microspheres for transient vascular embolization. Acta Biomater. 2014;10(3):1194–205. doi:10.1016/j.actbio.2013.11.028.

    Article  CAS  PubMed  Google Scholar 

  95. Salama SA, Nasr AB, Dubey RK, Al-Hendy A. Estrogen metabolite 2-methoxyestradiol induces apoptosis and inhibits cell proliferation and collagen production in rat and human leiomyoma cells: a potential medicinal treatment for uterine fibroids. J Soc Gynecol Investig. 2006;13(8):542–50. doi:10.1016/j.jsgi.2006.09.003.

    Article  CAS  PubMed  Google Scholar 

  96. Barchiesi F, Jackson EK, Fingerle J, Gillespie DG, Odermatt B, Dubey RK. 2-Methoxyestradiol, an estradiol metabolite, inhibits neointima formation and smooth muscle cell growth via double blockade of the cell cycle. Circ Res. 2006;99(3):266–74. doi:10.1161/01.RES.0000233318.85181.2e.

    Article  CAS  PubMed  Google Scholar 

  97. Ali H, Kilic G, Vincent K, Motamedi M, Rytting E. Nanomedicine for uterine leiomyoma therapy. Ther Deliv. 2013;4(2):161–75. doi:10.4155/tde.12.144.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  98. Muchmore DB. Raloxifene: a selective estrogen receptor modulator (SERM) with multiple target system effects. Oncologist. 2000;5(5):388–92. doi:10.1634/theoncologist.5-5-388.

    Article  CAS  PubMed  Google Scholar 

  99. Pavelić Ž, Škalko-Basnet N, Schubert R. Liposomal gels for vaginal drug delivery. Int J Pharm. 2001;219(1–2):139–49. doi:10.1016/S0378-5173(01)00637-8.

    Article  PubMed  Google Scholar 

  100. Patel A, Tyagi A, Sharma RK, Thakkar H. A gamma scintigraphy study to investigate uterine targeting efficiency of raloxifene-loaded liposomes administered intravaginally in New Zealand white female rabbits. Drug Deliv. 2016;23(9):3330–8. doi:10.1080/10717544.2016.1177137.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Evofem Biosciences, Inc., 12400 High Bluff Drive, Suite 600, San Diego, CA, 92130, USA

    David R. Friend

Authors
  1. David R. Friend
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David R. Friend.

Ethics declarations

Conflict of interest

The author declares that he has no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Friend, D.R. Drug delivery for the treatment of endometriosis and uterine fibroids. Drug Deliv. and Transl. Res. 7, 829–839 (2017). https://doi.org/10.1007/s13346-017-0423-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13346-017-0423-2

Keywords

Search

Navigation